Full-thickness Laparo-endoscopic Excision vs Laparoscopic Colectomy for Colonic Tumors
FlexLaC
Single-center, Randomized Trial: Full-thickness Laparo-endoscopic Excision vs Laparoscopic Colectomy for Colonic Tumors
1 other identifier
interventional
100
1 country
1
Brief Summary
Adenoma - carcinoma is a classic pathway of carcinogenesis. On this basis, timely removal of colon adenomas is a prophylactic measure to prevent colon cancer. The standard treatment of colorectal adenomas is endoscopic mucosal resection or submucosal dissection (ESD). In 10 - 15% of cases the ESD is impossible, due to the size of the tumor, inconvenient localisation in the area of the diverticulum or appendix, the presence of fibrosis in the submucosal layer (Currie AC framework IDEAL // Colorectal Disease. 2019. No. 9 (21). P. 1004-1016.), (Suzuki S. Short-term results of laparoscopic endoscopic cooperative surgery of colorectal tumors (LECS-CR) in cases of endoscopically inoperable colorectal tumors // Surgery today . 2019. No. 12 (49). S. 1051-1057.). In that cases the segmental colectomy is justified. An alternative to colectomy is a hybrid laparo-endoscopic surgery, which reduce postoperative hospital stay, incidence of complications and provide a comparable level of radicality (Lee SW, Garrett KA, Milsom JW Combined endoscopic and laparoscopic surgery (CELS) // Seminars on surgery of the colon and rectum. 2017. No. 1 (28). S. 24-29). Thus, the planned study will contribute to the introduction into practice of an alternative method of management with tumors of the colon without signs of invasive growth when the endoscopically removal is impossible.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Dec 2020
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2020
CompletedFirst Submitted
Initial submission to the registry
March 8, 2021
CompletedFirst Posted
Study publicly available on registry
March 17, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2023
CompletedAugust 25, 2022
August 1, 2022
2 years
March 8, 2021
August 24, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
R1 resection rate
In according to pathological examination
30 days
Secondary Outcomes (2)
The level of postoperative pain
10 days
The incidence and structure of postoperative complications
30 days
Study Arms (2)
laparoscopic resection
OTHERpatients with colonic adenomas who will undergo to laparoscopic segmental resection
full-thickness laparo-endoscopic colon adenomas excision
EXPERIMENTALpatients with colonic adenomas who will undergo to laparo-endoscopic full-thickness colon resection
Interventions
Full-thickness laparo-endoscopic removal of colon adenomas will be performed as follows: an endoscopist during intraoperative colonoscopy visualize the neoplasm, intra-luminary marks the margins of resection and stop at this in some cases. In another one: endoscopist start full-thickness removal of this lesion then the abdominal team during laparoscopy, with using laparoscopic technique, performe full-thickness resection of intestine wall with the tumor. Speciment extracted intralumenary or via minilaparotomy. Defect of the intestinal wall is sutured intracorporeally using laparoscopic technic. Desuflation, suturing of trocar sites.
Eligibility Criteria
You may qualify if:
- Patients age is 18 years and older
- Patients with colonic epithelial neoplasms without signs of invasive growth and not removable endoscopically
- Informed agreement
You may not qualify if:
- Positive regional lymph nodes
- FAP
- The presence of an intestinal stoma
- ASI \> III
- Patients with IBD
- Refusal of the patient to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ryzhikh National Medical Research Center of Coloproctology, Moscow, Russian Federation
Moscow, Russia
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Aleksey Kolosov
Ryzhikh National Medical Research Center of Coloproctology, Moscow, Russian Federation
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Masking Details
- patients with colon adenomas
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Head of colorectal surgery and oncology department
Study Record Dates
First Submitted
March 8, 2021
First Posted
March 17, 2021
Study Start
December 1, 2020
Primary Completion
December 1, 2022
Study Completion
April 1, 2023
Last Updated
August 25, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will not share